Keywords: Rheumatoid arthritis, Market, Pfizer, Roche, Chugai
Pipeline launches in the RA market will be major contributor to market growth to $11.5 billion In 2018
Article | 28 October 2009
Drugs with new mechanisms, in particular global behemoth Pfizer's oral JAK inhibitor CP-690,550 and Chugai/Roche's Actemra (tocilizumab), will launch ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
